panCELLa
panCELLa is a Toronto-area biotechnology company founded in 2015 that develops iPSC-derived cell therapeutics using CRISPR gene editing, operated by a small team of stem cell research founders.
- Company typePrivate
- Founded2015
- HeadquartersMississauga, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What panCELLa does
panCELLa is a privately held biotechnology company headquartered in Mississauga, in the Greater Toronto Area of Canada, founded in 2015. The company's described technical focus is on induced pluripotent stem cell (iPSC)-derived cell therapeutics, leveraging CRISPR-based gene editing applied to iPSC lines as its core platform. The leadership reflects a scientific-founder orientation: Andras Nagy serves as Founder, President and Chief Scientific Officer, bringing a stem cell biology research background, and Armand Keating serves as Founder and Chief Medical Officer, contributing hematology expertise. Mahendra Rao serves as Chief Executive Officer and Greg Hood as Chief Operating Officer, providing operational and corporate leadership around the founding scientific team. Headcount is reported at 1–10 employees, consistent with a lean, research-led organization.
The technical architecture implied by the firm's positioning combines iPSC reprogramming methodology with CRISPR-mediated gene editing — a platform used by a small set of competitors to engineer immune-evasive or disease-corrected cell lines for therapeutic application. No specific product candidates, indications, or pipeline stages are disclosed in the input, and no patents, trademarks, or regulatory actions are listed. The company maintains a corporate website (https://pancella.com/) but no product details, customer references, partnerships, or integration data are provided in the source material.
panCELLa's business model is preclinical and not yet revenue-generating based on the available evidence. The only disclosed capital event is a $1.0 million equity raise on 2018-01-24 from Chiefswood Holdings Limited. No customers, distribution channels, pricing models, or licensing arrangements appear in the input, indicating the firm is currently operating in a research and development phase rather than a commercial revenue phase. The absence of disclosed subsequent funding rounds in the source material limits visibility into the firm's current capitalization and runway position.
panCELLa firmographics
Firmographics- Name
- panCELLa
- Website
- https://pancella.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 1–10 employees
- Short description
- panCELLa is a Toronto-area biotechnology company founded in 2015 that develops iPSC-derived cell therapeutics using CRISPR gene editing, operated by a small team of stem cell research founders.
- Ownership category
- akta.pro rank
panCELLa industry classification
Industry- Product category
- Cell Therapy & Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where panCELLa is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Markets served
panCELLa business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
panCELLa product offering
Product offeringCore offering
panCELLa is a Toronto-area biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapeutics and CRISPR-based gene editing platforms. The company focuses on regenerative medicine applications, leveraging proprietary cell engineering technologies to create therapeutic cell products for clinical and research use. Its work spans cell therapy platform development for treating diseases using engineered stem cell-derived products.
Differentiator
Problem solved
Functional benefit
Companies that use panCELLa
Customer profileIdeal customer profiles1 record
panCELLa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
panCELLa partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
panCELLa competitors and assessment
Company assessmentOthers
- CCRM: Toronto-based Centre for Commercialization of Regenerative Medicine — a developer and manufacturer of cell and gene therapies. Not a direct competitor, but a key infrastructure partner and ecosystem peer for Toronto-based cell therapy companies like panCELLa.
Direct peers
- BlueRock Therapeutics: Bayer-owned iPSC-derived cell therapy developer focused on regenerative medicine for neurology, cardiology, and immunology. Highly comparable given panCELLa's iPSC and regenerative-medicine orientation, though materially better capitalized.
- Century Therapeutics: Clinical-stage iPSC-derived allogeneic cell therapy developer using gene editing (including CRISPR) to engineer immune cells. Closely mirrors panCELLa's iPSC + CRISPR platform positioning.
- Fate Therapeutics: Pioneer in iPSC-derived cell therapies, with multiple clinical-stage NK and T-cell programs. A clear benchmark for the category panCELLa is operating in.
- Notch Therapeutics: Toronto-based iPSC-derived T-cell therapy developer with programs in oncology. Highly comparable as both a Canadian iPSC cell therapy peer and a regional competitor.
- ViaCyte: Stem cell-derived cell therapy developer focused on regenerative medicine for diabetes. Comparable as a peer in pluripotent stem cell-derived therapeutics.
Regional players
- Aspect Biosystems: Vancouver-based biotechnology company developing cell therapies using proprietary bioprinting and stem cell technologies. Comparable as a Canadian regenerative-medicine cell therapy peer with platform-level ambitions.
Broad incumbents
- Sana Biotechnology: Clinical-stage cell and gene therapy company with programs spanning iPSC-derived cells, in vivo gene delivery, and ex vivo engineering. Broader platform than panCELLa but operates in the same iPSC + gene editing frontier.
- Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer pioneering off-the-shelf cell therapies. Comparable as a benchmark allogeneic cell therapy player in the broader category panCELLa addresses.
Emerging players
- Nkarta: Clinical-stage cell therapy company engineering NK cells for cancer and autoimmune disease. Comparable as a peer in next-generation engineered cell therapy with comparable size and stage profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
panCELLa social profiles
Digital presencepanCELLa financial estimates
Financial estimateRevenue estimate
Valuation estimate
panCELLa leadership team
Management profileNumber of profiles
Profiles4 records
panCELLa funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
panCELLa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about panCELLa
What does panCELLa do?
panCELLa is a Toronto-area biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapeutics and CRISPR-based gene editing platforms. The company focuses on regenerative medicine applications, leveraging proprietary cell engineering technologies to create therapeutic cell products for clinical and research use. Its work spans cell therapy platform development for treating diseases using engineered stem cell-derived products.
Is panCELLa a public or private company?
panCELLa is a private company. It is classified as venture growth investor backed.
When was panCELLa founded?
panCELLa was founded in 2015. It employs 1 to 10 people.
Where is panCELLa based?
panCELLa is headquartered in Mississauga, Canada, in the North America region.
Who are panCELLa's main competitors?
CCRM is listed as an others. Direct peers are BlueRock Therapeutics, Century Therapeutics, Fate Therapeutics, Notch Therapeutics and ViaCyte. Aspect Biosystems is listed as a regional player. Broad incumbents are Sana Biotechnology and Allogene Therapeutics. Nkarta is listed as an emerging player.
Does panCELLa have an API?
No public API is recorded for panCELLa.
What industry is panCELLa in?
panCELLa's product category is Cell Therapy & Regenerative Medicine. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414.